# Evaluation of Hepatic Pharmacokinetics for Grazoprevir (MK-5172) in Participants With Chronic Hepatitis C (MK-5172-022)

> **NCT01547312** · PHASE1 · WITHDRAWN · sponsor: **Merck Sharp & Dohme LLC**

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** Peg-Interferon
- **PROCEDURE:** Liver Samples from FNA
- **PROCEDURE:** Liver Samples from CNB
- **PROCEDURE:** Blood Samples
- **DRUG:** Ribavirin
- **DRUG:** 800 mg Grazoprevir
- **DRUG:** 100 mg Grazoprevir
- **PROCEDURE:** Liver samples from CNB and FNA

## Key facts

- **NCT ID:** NCT01547312
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-05
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2015-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01547312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01547312, "Evaluation of Hepatic Pharmacokinetics for Grazoprevir (MK-5172) in Participants With Chronic Hepatitis C (MK-5172-022)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT01547312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*